GlaxoSmithKline: Berenberg maintains 'buy' rating
(CercleFinance.com) - Berenberg maintains a "buy" rating on GlaxoSmithKline, with a target price of 1,790 pence, saying that the drugmaker's Cabotegravir experimental HIV treatment is "underappreciated.
"
GSK has announced success in a phase III trial for the long-acting HIV drug, which is being tested in combination with J&J's rilpivirine as a once-monthly injectable treatment, the German broker says.
"If a second trial reads out positively later this year, GSK could submit cabotegravir + rilpivirine to regulators within a few months," Berenberg writes in a note to clients.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
"
GSK has announced success in a phase III trial for the long-acting HIV drug, which is being tested in combination with J&J's rilpivirine as a once-monthly injectable treatment, the German broker says.
"If a second trial reads out positively later this year, GSK could submit cabotegravir + rilpivirine to regulators within a few months," Berenberg writes in a note to clients.
Copyright (c) 2018 CercleFinance.com. All rights reserved.